GRAIL, Inc.

GRAIL is a healthcare company developing and commercializing blood-based technologies for multi-cancer early detection. Its core product, Galleri, analyzes cell-free DNA methylation patterns to detect signals associated with multiple cancer types and predict the tissue or organ where a detected signal originated. The company’s operating model combines genomic sequencing, machine learning, clinical laboratory operations, large-scale clinical studies, and commercial distribution. GRAIL serves healthcare providers, health systems, employers, health plans, and consumers while pursuing broader regulatory approval and reimbursement. Its strategic focus centers on integrating multi-cancer screening into routine care, expanding clinical evidence, and extending Galleri into international markets.